STE · STERIS plc · Financials
Market Cap
$21.90B
Shares
97.50M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$5.94B
+8.7%
FY2026
Net Income
$782.3M
+27.3%
FY2026
Gross Margin
44.25%
+0.2pp
FY2026
Operating Margin
18.56%
+2.7pp
FY2026
Diluted EPS
$7.93
+27.9%
FY2026
Operating Cash Flow
$1.34B
+16.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2027 (G) | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $6.04B | $5.94B | $5.46B | $5.14B | $4.54B | $4.22BG | $3.11B | $3.03B | $2.78B | $2.62B | $2.61B | |
| — | $3.35B | $3.31B | $3.06B | $2.92B | $2.56B | $2.34B | $1.76B | $1.71B | $1.61B | $1.53B | $1.59B | |
| — | $2.68B | $2.63B | $2.4B | $2.22B | $1.98B | $1.88B | $1.34B | $1.32B | $1.17B | $1.09B | $1.03B | |
| — | — | 44.25% | 44.01% | 43.17% | 43.66% | 44.59% | 43.22% | 43.55% | 42.23% | 41.71% | 39.28% | |
| — | $115.1M | $112.9M | $107.6M | $103.7M | $98.48M | $86.66M | $66.33M | $65.55M | $63.04M | $60.78M | $59.4M | |
| — | $1.42B | $1.41B | $1.33B | $1.25B | $1.09B | $1.32B | $731.32M | $716.73M | $669.94M | $631.98M | $682.04M | |
| — | — | $268.2M | $276.2M | $268.3M | $259.68M | $264.61M | $86.51M | $74.53M | $98.75M | $70.2M | $68.61M | |
| — | $490.9M | $486.5M | $476.2M | $565.2M | $552.9M | $553.1M | $219.24M | $197.24M | $225.92M | $178.33M | $188.14M | |
| — | — | $3.4M | $62.3M | $44.4M | $485K | $48K | -$3.03M | $3.14M | $40.71M | $103K | $215K | |
| — | $1.54B | $1.52B | $1.54B | $1.38B | $1.19B | $1.41B | $794.73M | $782.95M | $763.96M | $692.86M | $800.01M | |
| — | $1.14B | $1.1B | $866.6M | $836.1M | $791.1M | $477.82M | $548.37M | $537.05M | $411.02M | $399.88M | $226.21M | |
| — | — | 18.56% | 15.87% | 16.27% | 17.44% | 11.31% | 17.65% | 17.72% | 14.77% | 15.26% | 8.66% | |
| — | $1.63B | $1.59B | $1.34B | $1.4B | $1.34B | $1.03B | $767.61M | $734.28M | $636.95M | $578.22M | $414.35M | |
| — | $60.6M | $60.7M | $86.3M | $144.35M | $107.96M | $89.49M | $37.18M | $40.28M | $45.02M | $50.63M | $44.52M | |
| — | -$52.6M | -$54.4M | -$70.4M | -$133.3M | -$110.84M | -$111.01M | -$30.84M | -$38.29M | -$42M | -$44.9M | -$41.56M | |
| — | $1.09B | $1.05B | $796.2M | $702.8M | $680.27M | $366.8M | $517.53M | $498.75M | $369.03M | $354.98M | $184.65M | |
| — | $280.8M | $262.2M | $184.7M | $149.5M | $124.07M | $82.34M | $120.66M | $90.9M | $64.28M | $63.36M | $74.02M | |
| — | $805M | $782.3M | $614.6M | $378.2M | $107.03M | $243.89M | $397.4M | $407.66M | $303.72M | $290.92M | $109.97M | |
| — | — | 13.18% | 11.26% | 7.36% | 2.36% | 5.77% | 12.79% | 13.45% | 10.92% | 11.1% | 4.21% | |
| — | $3.1M | $2.8M | $1.4M | $1.8M | -$1.22M | -$1.02M | -$530K | $200K | $1.03M | $707K | $666K | |
| — | $748.3M | $961.5M | $651M | $370.3M | -$3.87M | $95.32M | $571.62M | $331.97M | $134.23M | $543.3M | -$62.58M | |
| USD/shares | — | — | $7.97 | $6.24 | $3.83 | $1.07 | $2.50 | $4.66 | $4.81 | $3.59 | $3.42 | $1.29 |
| USD/shares | $11.10 – $11.30 | — | $7.93 | $6.20G | $3.81 | $1.07 | $2.48G | $4.63 | $4.76 | $3.55 | $3.39 | $1.28 |
| shares | — | — | 98.2M | 98.6M | 98.8M | 99.71M | 97.54M | 85.2M | 84.78M | 84.58M | 85.03M | 85.47M |
| shares | — | — | 98.7M | 99.1M | 99.4M | 100.25M | 98.33M | 85.9M | 85.64M | 85.47M | 85.71M | 86.09M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2026: $1.13B in buybacks, $1.57B in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
3.86×
Peer median 3.68×
EV/EBIT
20.42×
Peer median 22.98×
P/E (TTM)
28.32×
Peer median 30.34×
Peer medians compare against the 24 similar-size Medical Devices companies (of 145 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Healthcare Segment | $4,208,600,000 | $3,878,700,000 | $3,613,000,000 | $3,085,131,000 | — | — | — | — |
| Applied Sterilization Technologies | $1,138,500,000 | $1,038,600,000 | $954,000,000 | $914,431,000 | $685,912,000 | $627,147,000 | $555,127,000 | $513,287,000 |
| Life Science Member | $588,800,000 | $542,300,000 | $571,700,000 | $536,704,000 | $467,552,000 | $416,939,000 | $378,558,000 | $361,590,000 |
| Healthcare | — | $3,878,671,000 | $3,613,019,000 | $3,085,131,000 | $1,954,055,000 | $1,986,809,000 | $1,848,485,000 | — |
| Healthcare Products Member | — | — | — | — | — | $1,423,198,000 | $1,338,428,000 | $1,276,054,000 |
| Healthcare Specialty Services | — | — | — | — | — | $563,611,000 | $510,057,000 | $469,065,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $4,333,800,000 | $4,007,600,000 | $3,751,400,000 | $3,254,373,000 | $2,943,950,000 | $2,227,038,000 | $2,211,722,000 | $1,976,814,000 |
| Other Foreign Locations | $1,493,700,000 | $1,344,600,000 | $1,304,600,000 | $1,207,601,000 | $1,197,589,000 | $808,576,000 | $755,352,000 | $748,572,000 |
| Ireland | $108,500,000 | $107,300,000 | $82,700,000 | $74,292,000 | $81,864,000 | $71,905,000 | $63,821,000 | $56,784,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Product | $3,060,100,000 | $2,871,600,000 | $2,764,000,000 | $2,363,754,000 | $2,194,620,000 | $1,443,540,000 | $1,402,788,000 | $1,296,025,000 |
| Service | $2,875,800,000 | $2,587,900,000 | $2,374,700,000 | $2,172,512,000 | $2,028,783,000 | $1,663,979,000 | $1,628,107,000 | $1,486,145,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|
| Operating Segment All | $699,380,000 | $628,699,000 | $556,522,000 | $509,807,000 |
| Healthcare | $427,089,000 | $420,709,000 | $387,465,000 | — |
| Applied Sterilization Technologies | $310,648,000 | $270,917,000 | $221,828,000 | $196,297,000 |
| Life Science Member | $180,796,000 | $144,088,000 | $132,129,000 | $123,889,000 |
| Operating Segment Corp and Other | -$219,153,000 | -$207,015,000 | -$184,900,000 | -$162,999,000 |
| Healthcare Products Member | — | $356,419,000 | $323,684,000 | $294,162,000 |
| Healthcare Specialty Services | — | $64,217,000 | $64,222,000 | $58,458,000 |
Operating Margin by Segment (%)
| Component | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|
| Applied Sterilization Technologies | 45.3% | 43.2% | 40% | 38.2% |
| Life Science Member | 38.7% | 34.6% | 34.9% | 34.3% |
| Healthcare | 21.9% | 21.2% | 21% | — |
| Healthcare Products Member | — | 25% | 24.2% | 23.1% |
| Healthcare Specialty Services | — | 11.4% | 12.6% | 12.5% |
Key facts
CIK
1757898
CUSIP
G8473T100
13F (30d)
417 filings
413 filers
Visit website
Investor relations